(Reuters) -The EU's drug watchdog will request more data from makers of a class of diabetes and weight-loss drugs including Novo Nordisk's popular therapies Ozempic and Wegovy to further investigate suicidal thoughts in some patients taking them. "While at this point no conclusion can be drawn on a causal association, there are several issues that still need to be clarified," the European Medicines Agency (EMA) said in a statement on Friday, making it the first major global regulator to provided an update on such reviews. EMA's Pharmacovigilance Risk Assessment Committee (PRAC) will discuss the topic again at its meeting in April 2024, it added.
EU Extends Ozempic Review to Include More Weight-loss, Diabetes Drugs
europesun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europesun.com Daily Mail and Mail on Sunday newspapers.
EU Extends Ozempic Review to Include More Weight-loss, Diabetes Drugs
voanews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from voanews.com Daily Mail and Mail on Sunday newspapers.